

**REMARKS**

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Applicants have amended the claims to put them in conformity with the U.S. practice.

No new matter has been introduced.

Respectfully submitted,



**Yuriy P. Stercho, Ph.D.**  
Attorney for Applicants  
Registration No. 33,797

SMITHKLINE BEECHAM CORPORATION  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5018  
Facsimile (610) 270-5073  
n\yps\response\IP31853C1\preamd.doc

09939470-082401

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the specification:**

An Abstract of the Invention has been added.

**In the claims:**

Claims 4-12, 16, 18-20 and 22 have been amended as follows:

4. (Amended) A method according to [any one of] claim[s] 1 [to 3], wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound I).

5. (Amended) A method according to [any one of] claim[s] 1 to] 4, which comprises the administration of 2 to 12 mg of Compound (I).

6. (Amended) A method according to [any one of] claim[s] 1 to] 5, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I).

7. (Amended) A method according to [any one of] claim[s] 1 to] 6, which comprises the administration of 2 to 4mg of Compound (I).

8. (Amended) A method according to [any one of] claim[s] 1 to] 6, which comprises the method the administration of 4 to 8mg of Compound (I).

9. (Amended) A method according to [any one of] claim[s] 1 to] 6, which comprises the administration of 8 to 12 mg of Compound (I).

10. (Amended) A method according to [any one of] claim[s] 1 to 6] 7, which comprises the administration of 2 mg of Compound (I).

11. (Amended) A method according to [any one of] claim[s] 1 to 6] 8, which comprises the administration of 4 mg of Compound (I).

12. (Amended) A method according to [any one of] claim[s] 1 to 6] 8, which comprises the administration of 8 mg of Compound (I).

16. (Amended) A composition according to claim 14 [or claim 15], wherein the insulin secretagogue is glibenclamide, glipizide, gliclazide, glimepiride,

09939470-082401

tolazamide or tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glycopyramide, glycylamide or repaglinide.

18. (Amended) A composition according to [any one of] claim[s] 14 [to 17], wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-2,4-dione (Compound I).

19. (Amended) A composition according to [any one of] claim[s] 14 [to 17], which comprises 2 to 12 mg of Compound (I).

20. (Amended) A pharmaceutical composition comprising an insulin sensitiser, an insulin secretagogue and a pharmaceutically acceptable carrier therefor, for use as an active therapeutic substance.

22. (Amended) A composition according to [any one of] claim[s] 14, [20 or 21,] wherein the insulin sensitiser is (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2, 5, 7, 8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiazolidine-2,4-dione (or englitazone); or a pharmaceutically acceptable form thereof.

09039470-08240  
T04280-0246E660